Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2005 1
2006 1
2011 1
2014 4
2015 1
2016 2
2017 1
2018 2
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for vuillemenot b[au]
Your search for Guilleminot B[au] retrieved no results
Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
Ellinwood NM, Valentine BN, Hess AS, Jens JK, Snella EM, Jamil M, Hostetter SJ, Jeffery ND, Smith JD, Millman ST, Parsons RL, Butt MT, Chandra S, Egeland MT, Assis AB, Nelvagal HR, Cooper JD, Nestrasil I, Mueller BA, Labounek R, Paulson A, Prill H, Liu XY, Zhou H, Lawrence R, Crawford BE, Grover A, Cherala G, Melton AC, Cherukuri A, Vuillemenot BR, Wait JCM, O'Neill CA, Pinkstaff J, Kovalchin J, Zanelli E, McCullagh E. Ellinwood NM, et al. Among authors: vuillemenot br. J Pharmacol Exp Ther. 2022 Sep;382(3):277-286. doi: 10.1124/jpet.122.001119. Epub 2022 Jun 18. J Pharmacol Exp Ther. 2022. PMID: 35717448 Free PMC article.
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG. Leong SR, et al. Among authors: vuillemenot br. Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1. Blood. 2017. PMID: 27908880 Free PMC article.
Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
Vuillemenot BR, Kennedy D, Cooper JD, Wong AM, Sri S, Doeleman T, Katz ML, Coates JR, Johnson GC, Reed RP, Adams EL, Butt MT, Musson DG, Henshaw J, Keve S, Cahayag R, Tsuruda LS, O'Neill CA. Vuillemenot BR, et al. Mol Genet Metab. 2015 Feb;114(2):281-93. doi: 10.1016/j.ymgme.2014.09.004. Epub 2014 Sep 16. Mol Genet Metab. 2015. PMID: 25257657
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia.
Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, Dere RC, Carrasco-Triguero M, Lee MV, Saad OM, Liu L, He J, Su D, Xu K, Vuillemenot BR, Laing ST, Schutten M, Kozak KR, Zheng B, Polson AG, Kamath AV. Leipold DD, et al. Among authors: vuillemenot br. MAbs. 2018 Nov-Dec;10(8):1312-1321. doi: 10.1080/19420862.2018.1517565. Epub 2018 Oct 2. MAbs. 2018. PMID: 30183491 Free PMC article.
Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
Whiting RE, Narfström K, Yao G, Pearce JW, Coates JR, Castaner LJ, Jensen CA, Dougherty BN, Vuillemenot BR, Kennedy D, O'Neill CA, Katz ML. Whiting RE, et al. Among authors: vuillemenot br. Exp Eye Res. 2014 Aug;125:164-72. doi: 10.1016/j.exer.2014.06.008. Epub 2014 Jun 19. Exp Eye Res. 2014. PMID: 24954537 Free article.
16 results